Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Mi-RNAs and Specificity of Hs-TnT in Symptomatic ED Patients

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Intervention:  
Sponsors:   University Hospital Heidelberg;   German Heart Research Foundation
Not yet recruiting - verified April 2014

Rivaroxaban for Antiphospholipid Antibody Syndrome

Condition:   Antiphospholipid Antibody Syndrome
Intervention:   Drug: Rivaroxaban
Sponsors:   St. Joseph's Healthcare Hamilton;   Heart and Stroke Foundation of Canada;   Bayer;   Hamilton Health Sciences Corporation;   Jewish General Hospital;   University of Alberta;   The Ottawa Hospital;   Queen Elizabeth II Health Sciences Centre
Not yet recruiting - verified April 2014

Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction

Conditions:   Heart Failure, Diastolic;   Hypertension
Intervention:   Procedure: Renal denervation + medical therapy
Sponsor:   InCor Heart Institute
Recruiting - verified April 2014

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Condition:   Coronary Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Placebo
Sponsors:   University of Edinburgh;   AstraZeneca
Not yet recruiting - verified April 2014

Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Intervention:  
Sponsors:   British Cardiac Research Trust;   Royal Free Hospital NHS Foundation Trust;   North West London Hospitals NHS Trust;   Barnet and Chase Farm Hospitals NHS Trust;   Diabetes and Obesity Research Network;   Lund University;   Health Diagnostic Laboratory, Inc.
Recruiting - verified April 2014

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Not yet recruiting - verified April 2014

PATient Navigator to rEduce Readmissions

Conditions:   Chronic Obstructive Pulmonary Disease;   Heart Failure;   Sickle Cell Disease;   Myocardial Infarction;   Pneumonia;   Vascular Procedures
Interventions:   Behavioral: Hospital usual care;   Behavioral: Patient Navigator;   Behavioral: Peer-led telephone support line
Sponsors:   University of Illinois at Chicago;   Patient-Centered Outcomes Research Institute (PCORI);   University of Illinois at Urbana-Champaign;   Society of Hospital Medicine;   COPD Foundation;   University of Kentucky;   Mended Hearts;   American Heart Association;   Sickle Cell Disease Association of Illinois;   AcademyHealth;   The National Association of Social Workers Foundation;   Respiratory Health Association of Metropolitan Chicago;   University of Illinois Sickle Cell Patient Council;   National Jewish Health;   Olmsted Medical Center;   Baystate Medical Center;   Department of Veterans Affairs
Not yet recruiting - verified April 2014

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2014

Improving Adherence to Medication After Coronary Artery Bypass Surgery (CABG) in Older Adults

Condition:   Coronary Artery Bypass Grafting (CABG) Surgery
Interventions:   Behavioral: Motivational Interviewing (MI;   Behavioral: volitional intervention;   Behavioral: Routine discharge counseling
Sponsor:   Qazvin University Of Medical Sciences
Recruiting - verified April 2014

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

Condition:   Pulmonary Disease, Chronic Obstructive
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified April 2014

Detecting and Treating High Blood Pressure in Aboriginal Population and Low and Middle Income Countries

Conditions:   Hypertension;   Cardiovascular Disease;   Diabetes
Intervention:   Other: SMS text messaging
Sponsors:   Sunnybrook Health Sciences Centre;   Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2014

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Condition:   Immunodeficiency Virus, Human
Interventions:   Drug: Aspirin 81 mg table;   Drug: Atorvastatin 40 mg
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2013

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified April 2014

Antiplatelet Therapy Following Stent Implantation

Conditions:   Acute Myocardial Infarction;   Coronary Syndrome;   Angina, Unstable
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Recruiting - verified January 2014

BIOFLOW III Satellite-ELADIS

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   C.E.M. Biotronik, S.A.
Recruiting - verified February 2014

The Evaluation Of PF-04950615 (RN316) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

The Evaluation Of PF-04950615 (RN316), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?

Condition:   Clopidogrel
Interventions:   Drug: Clopidogrel;   Drug: Discontinue Clopidogrel
Sponsors:   Mount Sinai School of Medicine;   Doris Duke Charitable Foundation
Recruiting - verified April 2014

HsTnT in Stable Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:   Other: Progress of CHD
Sponsors:   University Hospital Heidelberg;   AstraZeneca
Active, not recruiting - verified April 2014

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

BIOFLOW III Asia Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Asia Pacific Pte Ltd
Recruiting - verified February 2014

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP

Conditions:   Prior Acute Myocardial Infarction;   Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l);   Reduced Left Ventricle Ejection Fraction (<50%);   Symptoms of Heart Failure (NYHA Class II-III)
Interventions:   Other: Cardiopulmonary exercise test;   Other: Echocardiogram
Sponsors:   Virginia Commonwealth University;   Novartis Pharmaceuticals
Active, not recruiting - verified April 2014

BIOFLOW-III Israel Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Israel
Recruiting - verified July 2013

Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels

Conditions:   Spinal Cord Injury;   Tetraplegia;   Quadraplegia;   Low HDL-c;   High LDL-c
Intervention:   Dietary Supplement: Omega-3 supplements
Sponsors:   University of Manitoba;   The Association of Rehabilitation Medicine in Manitoba
Recruiting - verified April 2014

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified April 2014

BIOFLOW-III Hungary Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Hungária Kft.
Recruiting - verified July 2013

BIOFLOW-III Canada Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Canada Inc
Not yet recruiting - verified June 2013

Application for Self-Monitoring of Cardiovascular Risk

Condition:   Coronary Artery Disease Which Requires Percutaneous Coronary Intervention(Balloon and/or Stent Treatment).
Intervention:   Device: Self Monitoring Software Application
Sponsor:   Mayo Clinic
Recruiting - verified April 2014

Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery

Conditions:   High Risk Non-cardiac Surgery;   Death;   Delirium;   Kidney Injury;   Myocardial Infarction;   Respiratory Failure;   Postoperative Infection
Intervention:   Other: Observational study
Sponsors:   University of Manitoba;   Canadian Anesthesia Research Foundation;   University of Manitoba Department of Anesthesia
Not yet recruiting - verified April 2014

The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

Conditions:   Antiphospholipid Syndrome;   Endothelial Dysfunction;   Hyperuricemia;   Gout;   Metabolic Syndrome
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting - verified April 2014

Sleep to Lower Elevated Blood Pressure

Conditions:   Hypertension;   Sleep Disorders;   Insomnia;   Cardiovascular Diseases
Intervention:   Behavioral: Online Sleep Education
Sponsors:   University College Hospital Galway;   Health Research Board, Ireland
Recruiting - verified April 2014

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified April 2014

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

Conditions:   ST Segment Elevation Myocardial Infarction (STEMI);   Allogeneic Mesenchymal Bone Marrow Cells
Intervention:   Biological: Stem cells
Sponsors:   Stemedica Cell Technologies, Inc.;   Mercy Gilbert Medical Center at AZ;   Chandler Regional Medical Center at Chandler AZ;   University of California, San Diego
Recruiting - verified April 2014

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Device: Evolocumab (AMG 145);   Device: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified April 2014

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

BIOFLOW-III Austria Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Vertriebs-GmbH
Recruiting - verified April 2013

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities

Condition:   Acute Coronary Syndrome
Intervention:   Procedure: Coronary angiogram
Sponsors:   University of Valencia;   Instituto de Salud Carlos III
Active, not recruiting - verified April 2014

Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study

Condition:   Myocardial Infarction (MI)
Intervention:  
Sponsor:   Abbott
Active, not recruiting - verified April 2014

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2014

ProspEctive First Evaluation in Chest Pain Trial

Conditions:   Chest Pain;   Shortness of Breath;   Suspected Acute Coronary Syndrome
Interventions:   Procedure: Coronary CT Angiography;   Procedure: Stress Test
Sponsor:   St. Luke's-Roosevelt Hospital Center
Recruiting - verified May 2012

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition:   Smoking Cessation
Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Sponsor:   Pfizer
Recruiting - verified April 2014

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelin
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2014

Intracoronary Administration of Levosimendan in Cardiac Surgery Patients

Condition:   Myocardial Stunning
Interventions:   Drug: levosimendan;   Drug: Vitamin B 12
Sponsor:   Tampere University Hospital
Recruiting - verified April 2014

Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function and Platelet Reactivity in Hypercholesterolemics.

Condition:   Hypercholesterolemia
Intervention:   Dietary Supplement: beetroot juice
Sponsors:   Queen Mary University of London;   British Heart Foundation
Completed - verified April 2014

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients

Condition:   Bleeding
Interventions:   Drug: Bivalirudin;   Drug: Unfractionated Heparin
Sponsor:   Clinica Mediterranea
Completed - verified April 2014

Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

Condition:   End Stage Renal Disease
Intervention:  
Sponsors:   University of Alberta;   Massachusetts General Hospital
Recruiting - verified April 2014

Liraglutide and Heart Failure in Type 2 Diabetes

Conditions:   Congestive Heart Failure;   Type 2 Diabetes Mellitus
Interventions:   Drug: liraglutide;   Drug: glimepiride;   Drug: Metformin
Sponsors:   Karolinska Institutet;   Thomas Nystrom;   Örebro University, Sweden
Recruiting - verified April 2014

Clearance Of Mucus In Stents

Conditions:   Lung Neoplasms;   Respiratory Failure;   Pneumonia;   Acute Coronary Syndromes;   Unstable Angina;   Myocardial Infarction;   Cardiac Arrhythmia;   Thromboembolic Disease
Interventions:   Other: Normal Saline;   Other: Sodium Bicarbonate
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified April 2014

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition:   Myocardial Infarction
Interventions:   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo;   Procedure: Percutaneous Coronary Intervention (PCI)
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra/Actemra];   Drug: etanercept
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified April 2014

Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Artery Disease;   General Anesthetic Drug Allergy;   Coronary Artery Bypass Graft Surgery
Interventions:   Drug: Xenon;   Drug: Sevoflurane;   Drug: Propofol
Sponsors:   Air Liquide Santé International;   Orion Corporation, Orion Pharma
Completed - verified April 2014

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Condition:   Atherosclerotic Cardiovascular Disease
Interventions:   Drug: anacetrapib;   Drug: placebo anacetrapib
Sponsors:   University of Oxford;   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

EXCEL Clinical Trial

Conditions:   Chronic Coronary Occlusion;   Unprotected Left Main Coronary Artery Disease;   Stent Thrombosis;   Vascular Disease;   Myocardial Ischemia;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Interventions:   Device: Percutaneous Coronary Intervention;   Procedure: CABG
Sponsor:   Abbott Vascular
Active, not recruiting - verified April 2014

Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease

Conditions:   Kawasaki Disease;   Aneurysm, Coronary
Intervention:   Drug: Atorvastatin
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Recruiting - verified April 2014

Anticoagulation in Stent Intervention

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol;   Drug: Acetylsalicylic Acid + clopidogrel
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified April 2014

Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

Condition:   Heart Failure
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   The George Institute;   Servier
Completed - verified April 2014

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781);   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781);   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Sponsor:   Bayer
Recruiting - verified April 2014

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

Conditions:   HIV;   Hyperlipidemia;   Hypertriglyceridemia;   HIV Infections
Intervention:   Drug: raltegravir
Sponsors:   The Miriam Hospital;   Tufts Medical Center;   Merck Sharp & Dohme Corp.
Completed - verified October 2013

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified April 2014

Antiepileptic Drugs and Vascular Risk Markers

Condition:   Subarachnoid Hemorrhage
Interventions:   Drug: phenytoin;   Drug: valproate;   Drug: levetiracetam
Sponsor:   Thomas Jefferson University
Terminated - verified April 2014

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Condition:   Antiphospholipid Syndrome
Intervention:  
Sponsor:   Duke University
Recruiting - verified February 2014

Hypertension Intervention Nurse Telemedicine Study (HINTS)

Condition:   Hypertension
Interventions:   Behavioral: Nurse Behavioral intervention with Home BP Telemonitoring;   Behavioral: Nurse Medication Management with Home BP Telemonitoring;   Behavioral: Nurse Combined intervention with Home BP Telemonitoring
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

Conditions:   Atherosclerosis;   Hypercholesterolemia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2014

Get CardioSmart

You're Invited